A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol-PM Plus Carboplatin® Compared to Genexol Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer.

Trial Profile

A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol-PM Plus Carboplatin® Compared to Genexol Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Ovarian cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Samyang Biopharmaceuticals Corporation
  • Most Recent Events

    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 24 Sep 2013 9151129 and 9153852 indicate that generic Taxol + carboplatin was the comparator group; NCT and 3088517 say Genexol + carboplatin
    • 16 Sep 2013 Data will be presented at the 2013 American Association for Cancer Research (AACR) conference, according to a Sorrento Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top